Becton Dickinson and (NYSE:BDX) vs. AIT Therapeutics (NYSE:AITB) Financial Review

Becton Dickinson and (NYSE:BDX) and AIT Therapeutics (OTCMKTS:AITB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for Becton Dickinson and and AIT Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Becton Dickinson and 0 3 6 1 2.80
AIT Therapeutics 0 0 0 0 N/A

Becton Dickinson and currently has a consensus price target of $266.40, indicating a potential upside of 5.93%. Given Becton Dickinson and’s higher probable upside, equities research analysts plainly believe Becton Dickinson and is more favorable than AIT Therapeutics.

Institutional & Insider Ownership

82.8% of Becton Dickinson and shares are held by institutional investors. 0.1% of Becton Dickinson and shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Becton Dickinson and has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, AIT Therapeutics has a beta of -0.31, indicating that its share price is 131% less volatile than the S&P 500.

Dividends

Becton Dickinson and pays an annual dividend of $3.08 per share and has a dividend yield of 1.2%. AIT Therapeutics does not pay a dividend. Becton Dickinson and pays out 28.0% of its earnings in the form of a dividend. Becton Dickinson and has raised its dividend for 47 consecutive years.

Profitability

This table compares Becton Dickinson and and AIT Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Becton Dickinson and 5.02% 14.78% 5.95%
AIT Therapeutics N/A N/A -100.76%

Valuation and Earnings

This table compares Becton Dickinson and and AIT Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Becton Dickinson and $15.98 billion 4.25 $311.00 million $11.01 22.84
AIT Therapeutics N/A N/A -$18.04 million ($3.01) -1.70

Becton Dickinson and has higher revenue and earnings than AIT Therapeutics. AIT Therapeutics is trading at a lower price-to-earnings ratio than Becton Dickinson and, indicating that it is currently the more affordable of the two stocks.

Summary

Becton Dickinson and beats AIT Therapeutics on 15 of the 16 factors compared between the two stocks.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, monoclonal antibodies and kits, reagent systems, bench-side solutions, and molecular indexing and next-generation sequencing sample preparation products, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, thoracic and abdominal drainage, and surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

AIT Therapeutics Company Profile

AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was founded in 2011 and is based in Garden City, New York.

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.